Key Points
- Edwards VP Donald Bobo, Jr. sold $1,818,028.80 of stock (22,680 shares) on April 2 under a pre-arranged Rule 10b5-1 plan, reducing his holding by 51.61% to 21,266 shares.
- The company reported Q4 EPS of $0.58 (missing estimates by $0.04) while revenue rose 13.3% to $1.57 billion, and set Q1 2026 guidance of $0.70–$0.76 per share.
- EW shares trade around the low $80s (opened $80.85), with a market cap of $46.6B and a P/E of 44.18; analysts have an average target of $95.96 and a consensus rating of "Moderate Buy."
Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Donald Bobo, Jr. sold 22,680 shares of the company's stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $80.16, for a total transaction of $1,818,028.80. Following the transaction, the vice president directly owned 21,266 shares in the company, valued at $1,704,682.56. The trade was a 51.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Edwards Lifesciences Stock Down 0.5%
EW stock opened at $80.85 on Friday. The company has a 50 day moving average price of $81.71 and a two-hundred day moving average price of $81.72. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. The stock has a market capitalization of $46.61 billion, a P/E ratio of 44.18, a PEG ratio of 2.12 and a beta of 0.95. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89.
Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). The business had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.Edwards Lifesciences's revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on EW shares. Stifel Nicolaus set a $110.00 price objective on shares of Edwards Lifesciences and gave the stock a "buy" rating in a report on Tuesday, January 20th. Wolfe Research raised shares of Edwards Lifesciences from a "peer perform" rating to an "outperform" rating and set a $92.00 price target for the company in a research report on Wednesday. TD Cowen raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating in a research note on Friday, January 9th. UBS Group restated a "neutral" rating and set a $94.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Finally, Wells Fargo & Company lifted their target price on Edwards Lifesciences from $96.00 to $100.00 and gave the company an "overweight" rating in a report on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $95.96.
View Our Latest Stock Report on Edwards Lifesciences
Institutional Investors Weigh In On Edwards Lifesciences
Several large investors have recently made changes to their positions in EW. J. Derek Lewis & Associates Inc. purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at $323,000. Rockefeller Capital Management L.P. increased its holdings in Edwards Lifesciences by 2.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 36,707 shares of the medical research company's stock valued at $3,129,000 after purchasing an additional 922 shares in the last quarter. World Investment Advisors increased its holdings in Edwards Lifesciences by 10.7% in the 4th quarter. World Investment Advisors now owns 39,986 shares of the medical research company's stock valued at $3,409,000 after purchasing an additional 3,877 shares in the last quarter. Corient Private Wealth LLC raised its position in Edwards Lifesciences by 20.7% in the fourth quarter. Corient Private Wealth LLC now owns 100,051 shares of the medical research company's stock valued at $8,547,000 after purchasing an additional 17,144 shares during the period. Finally, Hsbc Holdings PLC lifted its stake in shares of Edwards Lifesciences by 0.7% during the fourth quarter. Hsbc Holdings PLC now owns 2,148,974 shares of the medical research company's stock worth $183,188,000 after purchasing an additional 15,577 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.
About Edwards Lifesciences
(
Get Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
